Nurtec ODT and Vydura (rimegepant) is an oral CGRP receptor antagonist, a 75 mg orally disintegrating tablet taken for acute migraine or every other day to prevent episodic migraine, sold under the Nurtec ODT name in the US and the Vydura name in the EU and UK.
M Care Exports supplies Nurtec ODT and Vydura (rimegepant), the Pfizer oral gepant for migraine, to hospital pharmacies, importers and tender desks in the GCC, Africa and the UK. If you are looking for Nurtec ODT or Vydura, send the destination, the pack size and the quantity, and we quote per destination.
Rimegepant exporter and bulk supplier from India.
"We need a partner for Nurtec" is a typical enquiry from a neurology formulary lead or an importer. The name depends on the market: Nurtec ODT is the US name, and Vydura is the name on the EU and UK authorisations. M Care is a merchant-exporter and quotes against your specification, aligning the offer with your destination's registration route. Rimegepant is an oral tablet, not a cold-chain biological, so the quote turns on pack size, quantity, the registration route and the freight lane. Buyers who want an injectable CGRP option for prevention can compare our erenumab (Aimovig) and galcanezumab (Emgality) pages.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Oral CGRP receptor antagonist (gepant), sourced and documented for export.
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. The US Nurtec ODT label lists acute treatment of migraine with or without aura in adults, and preventive treatment of episodic migraine in adults. The EU and UK Vydura listings cover the same two uses, and the preventive indication is for adults with at least 4 migraine attacks per month. The dose is 75 mg. For acute use it is taken as needed, and the US label sets a maximum of 75 mg in 24 hours and says the safety of more than 18 doses in a 30-day period is not established. For prevention it is 75 mg every other day. The US label supplies a blister pack of 8 orally disintegrating tablets. The UK SmPC lists unit-dose blister packs of oral lyophilisates in 2, 8, 16 and 28, and notes that not all pack sizes may be marketed.
Active ingredient
Rimegepant sulfate. Oral CGRP receptor antagonist (gepant).
Forms and strengths
75 mg orally disintegrating tablet, blister pack of 8 (US); 75 mg oral lyophilisate, unit-dose blister packs of 2, 8, 16 or 28 (UK, not all marketed).
Indications
Rimegepant, an oral CGRP receptor antagonist for acute treatment of migraine with or without aura and preventive treatment of episodic migraine in adults. Sold as Nurtec ODT in the US and Vydura in the EU and UK, a room-temperature tablet supplied to GCC, African and UK buyers.
Administration
Oral, Sublingual. Orally disintegrating tablet (oral lyophilisate in the EU and UK).
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Buyers are hospital pharmacists and neurology formulary leads, MoH and hospital tender desks, and licensed importers and distributors in the GCC, Africa and the UK. Typical enquiries read "I'm looking for Nurtec ODT 75 mg for a neurology clinic" or "We need a partner for Vydura for a tender". Each destination has its own registration route, for example the Emirates Drug Establishment (EDE) in the UAE, NAFDAC in Nigeria and the MHRA in the UK, and we align the offer with it before quoting. A product that is not yet registered in your country is a separate conversation about the import route, which depends on the destination regulator and which M Care confirms per enquiry.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on rimegepant.
Rimegepant is a tablet that dissolves on or under the tongue, so handling matters more than reconstitution. The US label tells patients to use dry hands, peel back the foil of one blister, and not push the tablet through the foil. The tablet is taken straight after opening and not stored outside the blister. Storage differs by label. The US label states 20 to 25 °C. The UK SmPC states do not store above 30 °C, in the original package to protect from moisture, with a shelf life of 4 years. No refrigeration is needed, but build the lane to the stricter reading, and keep cartons dry. Clinically, the US label warns of hypersensitivity, which can occur days after a dose, new or worsening hypertension, and Raynaud's phenomenon. It says to avoid strong CYP3A4 inhibitors and strong or moderate CYP3A inducers, and to avoid a second dose within 48 hours with moderate CYP3A4 inhibitors or potent P-gp inhibitors. Severe hepatic impairment (Child-Pugh C) and end-stage renal disease are to be avoided.
The documentation pack a regulator actually asks for.
Rimegepant is a room-temperature oral product, so the quality file centres on the batch certificate of analysis, remaining shelf life on arrival and protection from moisture. The UK SmPC gives a shelf life of 4 years, and the EMA lists Pfizer Europe MA EEIG as the marketing authorisation holder, authorised on 25 April 2022. The EMA lists the medicine as under additional monitoring. The US label names Pfizer for adverse-event reporting. M Care documentation covers batch certificates, export documents and destination-aligned dossier support where the regulator requires it. We state the manufacturer's quality status per line before quoting, and make no claim for M Care itself beyond merchant-exporter documentation.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
Adjacent lines procurement desks order alongside rimegepant.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for rimegepant.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Rimegepant supply, the specific questions.
What decides the landed price of Nurtec ODT or Vydura for an importer?
We do not publish prices. The landed cost of rimegepant depends on the product and market name you need (Nurtec ODT or Vydura), the pack size, the quantity, the registration route in your destination and Incoterms. It is a room-temperature tablet, so there is no cold-chain freight line, but moisture protection and remaining shelf life still count. M Care Exports quotes per destination once you send the country, pack size and volume.
What is the Nurtec ODT 75 mg dose, and how often can it be taken?
The US label gives 75 mg taken orally as needed for acute migraine, with a maximum of 75 mg in 24 hours. It says the safety of more than 18 doses in a 30-day period has not been established. For prevention of episodic migraine the dose is 75 mg every other day. The UK SmPC states the acute dose as 75 mg as needed, once daily, and the preventive dose as 75 mg every other day.
Is there a generic of Nurtec ODT?
Not a marketed one in the US. The FDA has issued a tentative approval to Apotex for a rimegepant orally disintegrating tablet 75 mg ANDA. The letter says final approval cannot be granted until the patent-related conditions it sets out are met, so a tentative approval is not yet a launched generic. In the EU and UK, the authorised product on the EMA and emc pages we checked is Pfizer's Vydura. M Care confirms what is available for your destination at the time of quotation.
Is Nurtec available in the UAE, and what is it called in the UK and EU?
In the EU and UK the product is Vydura, authorised to Pfizer. The EMA lists the authorisation date as 25 April 2022. Nurtec ODT is the US name. For the UAE, product registration is with the Emirates Drug Establishment (EDE), and whether a given brand is registered depends on that register. We do not claim registration for any country without checking, and M Care confirms the route per enquiry.
Nurtec vs Ubrelvy: how do the labels differ?
Both are oral CGRP receptor antagonists. On the labels, Nurtec ODT (rimegepant) is indicated for acute treatment and for prevention of episodic migraine, at 75 mg, as an orally disintegrating tablet. Ubrelvy (ubrogepant) is indicated for acute treatment only, and its US label says it is not indicated for preventive treatment. Ubrelvy is dosed at 50 mg or 100 mg as needed, with a maximum of 200 mg in 24 hours. We compare presentation and label facts only, and do not recommend one product over the other.
What are the common Nurtec side effects, and is it for migraines only?
Nurtec ODT is labelled for migraine: acute treatment and preventive treatment of episodic migraine in adults. Other uses are not labelled indications. Nausea is the most common adverse reaction the US label reports. The label also warns of hypersensitivity reactions, hypertension and Raynaud's phenomenon. Safety and effectiveness in paediatric patients have not been established per the US label.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-11-08.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.